Currently out of the existing stock ratings of Luke Sergott, 68 are a HOLD (18.78%), 244 are a BUY (67.4%), 50 are a SELL (13.81%).

Luke Sergott

Work Performance Price Targets & Ratings Chart

Analyst Luke Sergott, currently employed at BARCLAYS, carries an average stock price target met ratio of 68.66% that have a potential upside of 14.97% achieved within 109 days.

Luke Sergott’s has documented 762 price targets and ratings displayed on 29 stocks. The coverage is on Basic Materials, Healthcare sectors.

Most recent stock forecast was given on BRKR, Bruker at 13-Feb-2026.

Wall Street Analyst Luke Sergott

Analyst best performing recommendations are on PACB (PACIFIC BIOSCIENCES OF CALIFORNIA).
The best stock recommendation documented was for SHC (SOTERA HEALTH CO) at 11/15/2022. The price target of $6 was fulfilled within 2 days with a profit of $0.97 (13.92%) receiving and performance score of 69.58.

Average potential price target upside

of $94.64 (7.8%) on MTD (METTLER-TOLEDO INTERNATIONAL).
of $73.96 (13.1%) on MEDP (MEDPACE HOLDINGS).
of $61.63 (11.48%) on TMO (THERMO FISHER SCIENTIFIC).

AVTR Avantor CERT Certara CTLT Catalent DHR Danaher ICLR ICON PLC ILMN Illumina IQV IQVIA Holdings OCDX Ortho Clinical Diagnostics Holdings plc SHC Sotera Health Co SYNH Syneos Health TWST Twist Bioscience Corp TMO Thermo Fisher Scientific PKI PerkinElmer WAT Waters A Agilent Technologies PACB Pacific Biosciences of California TXG 10X Genomics BRKR Bruker CRL Charles River Laboratories EXAS EXACT Sciences FTRE Fortrea Holdings RVTY Revvity GH Guardant Health MEDP Medpace Holdings MTD Mettler-Toledo International NTRA Natera QGEN Qiagen NV RGEN Repligen WST West Pharmaceutical Services

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Brandon Couillard (WELLS FARGO)